Issued Patents All Time
Showing 1–25 of 26 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 11998590 | Use of Mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation | David PEPIN | 2024-06-04 |
| 11518793 | Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation | David PEPIN | 2022-12-06 |
| 11135269 | Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation | David PEPIN | 2021-10-05 |
| 11084860 | Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases | Demetrios Vavvas, David PEPIN, Mien Van HOANG | 2021-08-10 |
| 10258668 | Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein | Demetrios Vavvas, David PEPIN, Mien Van HOANG, Robert H. Brown, Jr., Guangping Gao | 2019-04-16 |
| 9791449 | Ovarian cancer stem cells and methods of isolation and uses thereof | David T. MacLaughlin, Jose Teixeira | 2017-10-17 |
| 9289492 | Collecting ovarian cancer stem cells from ovarian cancer cells | Paul P Szotek, David T. MacLaughlin, Frederic Preffer, Rafael Pieretti-Vanmarcke, David Michael Dombkowski | 2016-03-22 |
| 9260759 | Pyrazoloanthrone and derivatives thereof for the treatment of cancers expressing MISRII | Jose Teixeira | 2016-02-16 |
| 7078032 | Delivery of therapeutic biologicals from implantable tissue matrices | David T. MacLaughlin, Joseph P. Vacanti, Peter T. Masiakos | 2006-07-18 |
| 6692738 | Delivery of therapeutic biologicals from implantable tissue matrices | David T. MacLaughlin, Joseph P. Vacanti, Peter T. Masiakos | 2004-02-17 |
| 6673352 | Use of Mullerian inhibiting substance for treating excess androgen states | Jose Teixeira, Eric Fynn-Thompson | 2004-01-06 |
| 5912224 | Methods and compositions for enhancing cellular response to TGF-.beta. ligands | Tongwen Wang | 1999-06-15 |
| 5661126 | Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression | Tai Wai Chin, Robert L. Parry, James Epstein, Richard C. Ragin, David T. MacLaughlin +1 more | 1997-08-26 |
| 5547854 | DNA encoding a receptor for Mullerian inhibitory substance, misr1, and corresponding vectors, cells, probes, and recombinant methods | Michael P. Gustafson, Wei He | 1996-08-20 |
| 5538892 | Nucleic acids encoding a TGF-.beta. type 1 receptor | Michael P. Gustafson, Wei He, Xiao-Fan Wang | 1996-07-23 |
| 5427780 | Composition comprising Mullerian inhibiting substance-like polypeptides | Richard Cate | 1995-06-27 |
| 5310880 | Purification of Mullerian inhibiting substance | Richard C. Ragin, David T. MacLaughkin | 1994-05-10 |
| 5198420 | Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome | Elizabeth A. Catlin | 1993-03-30 |
| 5047336 | DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides | Richard Cate | 1991-09-10 |
| 5011687 | Purified Mullerian inhibiting substance and process for treating human ovarian cancer cells | David A. Swann | 1991-04-30 |
| 5010055 | Use of EGF to reverse the contraceptive activity of MIS | — | 1991-04-23 |
| 4792601 | Monoclonal antibody to mullerian inhibiting substance | Gerald P. Budzik, Meredith Mudgett-Hunter | 1988-12-20 |
| 4753794 | Use of mullerian inhibiting substance as a contraceptive agent | — | 1988-06-28 |
| 4510131 | Purified Mullerian Inhibiting Substance and method of use | Gerald P. Budzik, David A. Swann | 1985-04-09 |
| 4487833 | Method of preparing hybridomas and of purifying immunogenic materials | Gerald P. Budzik, Meredith Mudgett-Hunter | 1984-12-11 |